A detailed history of Tower Research Capital LLC (Trc) transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 724 shares of BPMC stock, worth $63,299. This represents 0.0% of its overall portfolio holdings.

Number of Shares
724
Previous 11,114 93.49%
Holding current value
$63,299
Previous $1.2 Million 94.49%
% of portfolio
0.0%
Previous 0.02%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$84.1 - $120.5 $873,798 - $1.25 Million
-10,390 Reduced 93.49%
724 $66,000
Q2 2024

Aug 13, 2024

BUY
$85.18 - $108.78 $719,174 - $918,429
8,443 Added 316.1%
11,114 $1.2 Million
Q1 2024

May 15, 2024

SELL
$73.17 - $99.79 $343,825 - $468,913
-4,699 Reduced 63.76%
2,671 $253,000
Q4 2023

Feb 13, 2024

BUY
$43.96 - $92.84 $282,970 - $597,611
6,437 Added 689.92%
7,370 $679,000
Q3 2023

Nov 14, 2023

SELL
$46.9 - $66.0 $292,609 - $411,774
-6,239 Reduced 86.99%
933 $46,000
Q2 2023

Aug 14, 2023

BUY
$42.2 - $66.37 $206,737 - $325,146
4,899 Added 215.53%
7,172 $453,000
Q1 2023

May 09, 2023

BUY
$37.97 - $50.0 $47,614 - $62,700
1,254 Added 123.06%
2,273 $102,000
Q4 2022

Feb 10, 2023

SELL
$41.06 - $66.48 $417,744 - $676,367
-10,174 Reduced 90.9%
1,019 $45,000
Q3 2022

Nov 10, 2022

SELL
$49.93 - $77.7 $223,985 - $348,562
-4,486 Reduced 28.61%
11,193 $737,000
Q2 2022

Aug 15, 2022

BUY
$45.23 - $70.15 $656,468 - $1.02 Million
14,514 Added 1245.84%
15,679 $792,000
Q1 2022

May 12, 2022

SELL
$54.1 - $110.08 $83,476 - $169,853
-1,543 Reduced 56.98%
1,165 $75,000
Q4 2021

Feb 14, 2022

BUY
$94.25 - $115.99 $2,262 - $2,783
24 Added 0.89%
2,708 $290,000
Q3 2021

Nov 15, 2021

SELL
$80.98 - $109.47 $2,753 - $3,721
-34 Reduced 1.25%
2,684 $276,000
Q2 2021

Aug 16, 2021

SELL
$82.78 - $101.0 $279,382 - $340,875
-3,375 Reduced 55.39%
2,718 $239,000
Q1 2021

May 17, 2021

BUY
$90.71 - $108.28 $191,035 - $228,037
2,106 Added 52.82%
6,093 $593,000
Q4 2020

Feb 16, 2021

SELL
$92.08 - $124.48 $176,977 - $239,250
-1,922 Reduced 32.53%
3,987 $447,000
Q3 2020

Nov 16, 2020

SELL
$66.45 - $92.7 $39,072 - $54,507
-588 Reduced 9.05%
5,909 $547,000
Q2 2020

Aug 13, 2020

BUY
$57.09 - $79.27 $370,913 - $515,017
6,497 New
6,497 $507,000
Q1 2020

May 15, 2020

SELL
$48.11 - $82.22 $236,027 - $403,371
-4,906 Closed
0 $0
Q4 2019

Feb 07, 2020

BUY
$66.73 - $82.59 $323,707 - $400,644
4,851 Added 8820.0%
4,906 $393,000
Q3 2019

Nov 05, 2019

BUY
$72.9 - $101.41 $2,041 - $2,839
28 Added 103.7%
55 $4,000
Q2 2019

Aug 13, 2019

BUY
$73.54 - $97.8 $73 - $97
1 Added 3.85%
27 $3,000
Q1 2019

May 14, 2019

BUY
$48.7 - $86.6 $1,266 - $2,251
26 New
26 $2,000
Q4 2018

Feb 14, 2019

SELL
$45.57 - $74.26 $5,787 - $9,431
-127 Closed
0 $0
Q3 2018

Nov 13, 2018

BUY
$58.91 - $78.32 $7,010 - $9,320
119 Added 1487.5%
127 $10,000
Q2 2018

Aug 15, 2018

BUY
$60.96 - $101.18 $487 - $809
8 New
8 $1,000
Q1 2018

May 15, 2018

SELL
$73.28 - $102.95 $184,152 - $258,713
-2,513 Closed
0 $0
Q4 2017

Feb 09, 2018

BUY
$62.91 - $88.32 $142,931 - $200,663
2,272 Added 942.74%
2,513 $190,000
Q3 2017

Nov 14, 2017

BUY
$42.37 - $69.67 $10,211 - $16,790
241
241 $17,000

Others Institutions Holding BPMC

About Blueprint Medicines Corp


  • Ticker BPMC
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,719,600
  • Market Cap $5.22B
  • Description
  • Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...
More about BPMC
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.